Key result
Renal denervation failed to significantly reduce office or ambulatory systolic blood pressure compared to sham control in patients with resistant hypertension, showing a non-significant intergroup difference of 2.39 mm Hg.
Why the study?
Does renal sympathetic denervation reduce blood pressure in patients with resistant hypertension?
Does renal sympathetic denervation reduce blood pressure in patients with resistant hypertension?
Mean Difference: 2.39
p-value: p=not statistically significant
Definitive clinical evidence showing that renal denervation reduces either blood pressure or clinical events is needed before it becomes a mainstream therapy for resistant hypertension.
When renal sympathetic denervation, an endovascular procedure designed to treat resistant hypertension, failed to meet its efficacy goal in the SYMPLICITY HTN-3 trial,[1][1] the news was disappointing. See related article, page [681][2] In this issue of the Cleveland Clinic Journal of Medicine ,
No takes yet. Share an insight, caveat, or question.
Denktas et al. (2017) conducted an editorial in Resistant hypertension (n=535). Renal-artery denervation vs. Sham control / medical therapy alone was evaluated on Reduction in office systolic blood pressure at 6 months (Intergroup difference of 2.39 mm Hg, p=not statistically significant). Renal denervation failed to significantly reduce office or ambulatory systolic blood pressure compared to sham control in patients with resistant hypertension, showing a non-significant intergroup difference of 2.39 mm Hg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: